ABOS Stock Analysis: Buy, Sell, or Hold?
ABOS - Acumen Pharmaceuticals, Inc. Common Stock
$2.23
0.06 (2.53%)
▲
5d:
-15.4%
30d:
-2.84%
90d:
-17.29%
WAIT
LOW Confidence
Analysis Updated: Jul 17, 2026 12:00 AM ET
Earnings: Aug 11, 2026
24d
Get Alerted When ABOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ABOS is down 15.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ABOS is down 15.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABOS is currently trading at $2.23, which is considered slightly low relative to its 30-day fair value range of $2.26 to $2.64.
Technical Outlook: Technically, ABOS is in a strong downtrend. Immediate support is located at $2.09, while resistance sits at $2.78.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+241.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABOS is in a strong downtrend. Immediate support is located at $2.09, while resistance sits at $2.78.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+241.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.26 -
$2.64
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 241.0% below Wall St target ($7.40)
- WARNING: Recommendation downgraded due to -15.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.26 -
$2.64
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.09
Resistance Level
$2.78
Current Trend
Strong Downtrend
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.44
Wall Street Target
$7.40
(+241.0%)
Share & Embed Analysis
Last updated: July 17, 2026 3:27 PM ET
Data refreshes hourly during market hours. Next update: 4:27 PM
Data refreshes hourly during market hours. Next update: 4:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Siemers
SELL
895 shares
2026-01-22
Matt Zuga
SELL
1687 shares
2026-01-22
Russell Barton
SELL
462 shares
2026-01-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 47 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 51 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 64 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 57 HOLD |
